Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary.
Hellstern
P
P
Institute of Hemostaseology and Transfusion Medicine, City Hospital, Laudwighafen, Germany. peterhellstern@medicusnet.de
Halbmayer
W M
WM
Köhler
M
M
Seitz
R
R
Müller-Berghaus
G
G
D001779:Blood Coagulation Factors / Q000592:standards / Q000627:therapeutic use*; D020147:Coagulation Protein Disorders / Q000188:drug therapy; D000075202:Contraindications; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy; D011516:Prothrombin / Q000592:standards / Q000627:therapeutic use*; D012015:Reference Standards; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy; D014813:Vitamin K Deficiency / Q000188:drug therapy
D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D011516:Prothrombin; D006493:Heparin